Orexigen Therapeutics (OREX) fell Wednesday after the FDA delayed its decision on the company's obesity pill Contrave until Sept. 11.

Amid accusations the drug maker misled investors and patients about the safety of its drug, Orexigen Therapeutics is now feuding with Takeda Pharmaceutical, its marketing partner, over the cost of ...

OREX's obesity drug candidate Contrave heads to its FDA advisory panel next Tuesday, December 7, wrapping up this year's trifecta of obesity drug candidates at the FDA. Contrave has shown solid ...

Orexigen Therapeutics Inc (NASDAQ:OREX), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the ...

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses ...

Orexigen Therapeutics Inc. said Monday that its obesity-drug candidate Contrave met its main goals in three late-stage clinical trials, and also surpassed a Food and Drug Administration ...

Orexigen Therapeutics (OREX) stock is up after the company said the European Union review of its drug is progressing, as it reported better than expected third quarter earnings this morning.

Before you break out the Doritos and phone your doctor, here are five reasons to be cautious about the potential for success of Orexigen's new obesity treatment, Contrave.

SAN DIEGO — Drug maker Orexigen Therapeutics said it had identified a "clear and feasible path" for the approval of its drug for treating obesity by working with the Food and Drug Administration.

Coming up on June 10th, 2014, Orexigen Therapeutics expects a Food and Drug Administration (FDA) for it’s weight loss drug NB32 (Contrave).

DALLAS, June 2, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Orexigen Therapeutics Inc. (Nasdaq:OREX). The report includes financial, comparative and ...

The first of three new diet drugs -- Vivus (VVUS)'s Qnexa -- comes up for a vote at the FDA on July 15, and its fate will send a strong signal about the likelihood of its two rivals, Arena (ARNA ...